A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.AstraZeneca said it is doubling down on its investment in its U.

AstraZeneca raised its full-year guidance after third-quarter results topped analysts’ expectations, boosted by its cancer and diabetes medicines, and laid out plans for a multibillion-dollar investment in the U.

By Maggie Fick and Yadarisa Shabong (Reuters) -Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong demand for its cancer and rare diseases medicines,

KEY TAKEAWAYS British drugmaker AstraZeneca increased its full-year sales outlook on booming demand for its cancer and rare-disease drugs, and said it plans to invest $3.5 billion in its U.S. business by the end of 2026.

The pharmaceutical giant raised its full-year guidance after third-quarter revenue and core earnings per share topped analysts’ expectations.